KYMR Q2 EPS Forecast Raised by Brookline Capital Markets

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Analysts at Brookline Capital Markets lifted their Q2 2026 earnings per share estimates for Kymera Therapeutics in a research note issued on Thursday, April 30th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.97). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.49) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics’ Q3 2026 earnings at ($1.11) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($3.57) EPS, FY2027 earnings at ($4.27) EPS, FY2028 earnings at ($4.73) EPS, FY2029 earnings at ($4.29) EPS and FY2030 earnings at ($4.68) EPS.

KYMR has been the subject of several other research reports. Jefferies Financial Group started coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price target for the company. Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Stephens upped their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. Finally, Barclays lifted their price objective on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $118.70.

Kymera Therapeutics Stock Performance

KYMR opened at $83.59 on Tuesday. The company has a market cap of $6.88 billion, a PE ratio of -23.41 and a beta of 2.06. The stock has a 50-day moving average of $84.52 and a 200-day moving average of $76.47. Kymera Therapeutics has a 52-week low of $28.06 and a 52-week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.82) earnings per share.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC lifted its position in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the period. Larson Financial Group LLC grew its holdings in shares of Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $63,000. Bessemer Group Inc. grew its holdings in shares of Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares in the last quarter.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at approximately $60,130,760.70. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Bruce Booth sold 81,866 shares of Kymera Therapeutics stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58. Following the completion of the transaction, the director owned 675,341 shares in the company, valued at $60,868,484.33. The trade was a 10.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 380,734 shares of company stock valued at $32,193,902 in the last ninety days. Company insiders own 16.01% of the company’s stock.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Q1 results and follow-up analyst lift — Kymera beat Q1 revenue and EPS expectations, and coverage pieces note analysts are raising near-term estimates, supporting positive sentiment around execution and revenue growth. Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
• Positive Sentiment: Near?term estimate upgrades from Brookline — The firm raised its Q2 2026 EPS forecast (improved from ?$0.97 to ?$0.62) and lifted FY2026 (from ?$3.76 to ?$3.57), suggesting the analyst sees better near?term revenue or lower near?term dilution/expense than previously modeled. This can be supportive for the stock if it signals improving fundamentals.
• Positive Sentiment: Promising preclinical data for KT?579 — Kymera presented preclinical IBD results showing KT?579 (oral IRF5 degrader) had activity comparable or superior to approved/clinically active therapies in models, which de?risks the program and increases its clinical / commercial upside if translated to humans. Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
• Neutral Sentiment: Corporate milestone / visibility event — Kymera rang the opening bell for its 10?year anniversary (ceremonial, increases visibility but no direct operational impact). LIVE: Kymera Therapeutics, Inc. Rings the Opening Bell in Celebration of its 10-Year Anniversary
• Negative Sentiment: Some later?period estimate cuts from Brookline — The same Brookline note lowered Q3 2026 (from ?$1.01 to ?$1.11) and Q4 2026 (to ?$1.13 from ?$0.84) and trimmed FY2027 expectations (worse from prior), indicating expectations for deeper/longer losses beyond the near term. That raises the possibility of continued dilution or heavy R&D spend, which can cap valuation until clinical readouts translate to clearer revenue prospects.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.